Introduction Glaucoma is a progressive optic neuropathy and the leading cause of
irreversible vision loss. By 2040, the number of individuals with glaucoma is expected to …

Medical therapy is generally the initial treatment approach of glaucoma and ocular
hypertension. Glaucoma medications decrease intraocular pressure (IOP) through 2 main …

Introduction: Glaucoma is the second leading cause of blindness in the world and current
pharmacotherapies for glaucoma have remained relatively unchanged (with the exception of …

Introduction: Intraocular pressure (IOP) is the most significant modifiable risk factor to
prevent onset or progression of glaucoma. Glaucoma prevalence continues to increase …

Glaucoma refers to a collection of progressive optic neuropathies that can lead to
irreversible damage to retinal ganglion cells and their axons, and eventual loss of vision if …

In the last 5 years, numerous novel ocular hypotensive agents have been introduced for the
control of intraocular pressure (IOP). Clinicians now have more options than ever in medical …

Objectives: To analyse drug development for open-angle glaucoma during the last 20 years.
Methods: Research was performed by referring to clinical trials registered at the International …

Introduction: Prostaglandin F2α analogs were the first prostaglandin agonists introduced for
glaucoma treatment. Thanks to their efficacy and favorable tolerability they set a high bar in …

Although challenges in medical treatment of glaucoma exist, particularly in patient
adherence, medical therapy remains the first line treatment for almost all glaucoma patients …

Glaucoma is a multifactorial optic neuropathy in which there is a characteristic acquired loss
of retinal ganglion cells, at levels beyond normal age-related baseline loss, and …